India registers CKMS observational registry backed by Sun Pharmaceutical
A new multicentre registry will track cardiovascular-kidney-metabolic syndrome in Indian adults, listed as not yet recruiting.
This week's item covers a newly registered observational study tracking a cross-organ disease category in Indian hospitals.
- The "Cardiovascular-Kidney-Metabolic Syndrome Registry" (NCT07718789) is an observational study led by the Centre for Chronic Disease Control, India, with Sun Pharmaceutical Industries Limited listed as a collaborator. The study is expected to include approximately 2250 adults from five tertiary care hospitals in India.1 Status is not yet recruiting, with an estimated start date of 2026-07-24 and estimated primary completion of 2027-12-31.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.